表紙
市場調査レポート

閉経後骨粗鬆症:パイプライン製品の分析

Post Menopausal Osteoporosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213136
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
閉経後骨粗鬆症:パイプライン製品の分析 Post Menopausal Osteoporosis - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 85 Pages
概要

閉経後骨粗鬆症とは、骨粗鬆症のもっとも一般的な形態であり、閉経後の女性の多くが罹ります。背痛や身長低下、前屈姿勢などの脊椎変形といった症状があります。年齢、性別、家族歴、骨構造、体重などのリスクファクターがあり、ホルモン補充療法(HRT)、ビタミンD3誘導体の投与などの治療法があります。

当レポートでは、世界における閉経後骨粗鬆症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

閉経後骨粗鬆症の概要

治療薬の開発

  • パイプライン製品の概要

閉経後骨粗鬆症:企業で開発中の治療薬

閉経後骨粗鬆症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

閉経後骨粗鬆症:企業で開発中の製品

閉経後骨粗鬆症の治療薬開発に従事している企業

  • Amgen Inc.
  • BiologicsMD, Inc.
  • Clonz Biotech Private Limited
  • Eli Lilly and Company
  • Enteris BioPharma, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Paras Biopharmaceuticals Finland Oy
  • Radius Health, Inc.

閉経後骨粗鬆症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

閉経後骨粗鬆症:最近のパイプライン動向

閉経後骨粗鬆症:休止中のプロジェクト

閉経後骨粗鬆症:開発が中止された製品

閉経後骨粗鬆症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7873IDB

Summary

Global Markets Direct's, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2016', provides an overview of the Post Menopausal Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
  • The report reviews pipeline therapeutics for Post Menopausal Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post Menopausal Osteoporosis therapeutics and enlists all their major and minor projects
  • The report assesses Post Menopausal Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post Menopausal Osteoporosis Overview
  • Therapeutics Development
    • Pipeline Products for Post Menopausal Osteoporosis - Overview
  • Post Menopausal Osteoporosis - Therapeutics under Development by Companies
  • Post Menopausal Osteoporosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Post Menopausal Osteoporosis - Products under Development by Companies
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • BiologicsMD, Inc.
    • Clonz Biotech Private Limited
    • Eli Lilly and Company
    • Enteris BioPharma, Inc.
    • Ligand Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Oncobiologics, Inc.
    • Paras Biopharmaceuticals Finland Oy
    • Radius Health, Inc.
  • Post Menopausal Osteoporosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abaloparatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • blosozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMD-1111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • calcitonin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Postmenopausal Osteoporosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • odanacatib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romosozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Post Menopausal Osteoporosis - Recent Pipeline Updates
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2016: Radius Presents Analysis Results on Fracture Risk Reduction in Phase 3 ACTIVE Trial for Investigational Drug Abaloparatide-SC at the ENDO 2016 Annual Meeting
      • Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
      • Mar 31, 2016: ermonix Pharmaceuticals to Give Lasofoxifene Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease
      • Mar 30, 2016: Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
      • Feb 21, 2016: Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
      • Jan 04, 2016: EMA started the evaluation of Richter's marketing authorization application for biosimilar teriparatide
      • Nov 17, 2015: Radius Health Has Submitted a Marketing Authorization Application for the Investigational Drug Abaloparatide-SC for the Treatment of Postmenopausal Osteoporosis in Europe
      • Oct 19, 2015: Enteris BioPharma's Formulation Technology Enables Oral Delivery of Tarsa Therapeutics' TBRIA - the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
      • Oct 19, 2015: TARSA Therapeutics' NDA For TBRIA, The First Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis, Accepted For Filing
      • Oct 12, 2015: Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by BiologicsMD, Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma, Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016
  • Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Post Menopausal Osteoporosis - Dormant Projects, H1 2016
  • Post Menopausal Osteoporosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top